Similarly, targeting other driver oncogenes with specific siRNAs in conjunction with mutant p53 will likely enhance the therapeutic effects, and one could envisage a cocktail of siRNAs against the major genetic alterations in each cancer type would likely be clinically very beneficial. This evidence concerns the gene TP53 and cancer.